tetano
Editor, Senior Moderator
Curr Res Microb Sci
. 2023 Dec 2:6:100208.
doi: 10.1016/j.crmicr.2023.100208. eCollection 2024. Clinical development of antivirals against SARS-CoV-2 and its variants
Qiaoshuai Lan[SUP] 1 2 [/SUP], Yan Yan[SUP] 1 [/SUP], Guangxu Zhang[SUP] 1 [/SUP], Shuai Xia[SUP] 1 [/SUP], Jie Zhou[SUP] 2 3 4 [/SUP], Lu Lu[SUP] 1 [/SUP], Shibo Jiang[SUP] 1 [/SUP]
Affiliations
The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants.
Keywords: Antivirals; COVID-19; Host factor; SARS-CoV-2; Variants; Viral factor.
. 2023 Dec 2:6:100208.
doi: 10.1016/j.crmicr.2023.100208. eCollection 2024. Clinical development of antivirals against SARS-CoV-2 and its variants
Qiaoshuai Lan[SUP] 1 2 [/SUP], Yan Yan[SUP] 1 [/SUP], Guangxu Zhang[SUP] 1 [/SUP], Shuai Xia[SUP] 1 [/SUP], Jie Zhou[SUP] 2 3 4 [/SUP], Lu Lu[SUP] 1 [/SUP], Shibo Jiang[SUP] 1 [/SUP]
Affiliations
- PMID: 38149085
- PMCID: PMC10750039
- DOI: 10.1016/j.crmicr.2023.100208
The unceasing global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) calls for the development of novel therapeutics. Although many newly developed antivirals and repurposed antivirals have been applied to the treatment of coronavirus disease 2019 (COVID-19), antivirals showing satisfactory clinical efficacy are few in number. In addition, the loss of sensitivity to variants of concern (VOCs) and lack of oral bioavailability have also limited the clinical application of some antivirals. These facts remind us to develop more potent and broad-spectrum antivirals with better pharmacokinetic/pharmacodynamic properties to fight against infections from SARS-CoV-2, its variants, and other human coronaviruses (HCoVs). In this review, we summarize the latest advancements in the clinical development of antivirals against infections by SARS-CoV-2 and its variants.
Keywords: Antivirals; COVID-19; Host factor; SARS-CoV-2; Variants; Viral factor.